search
Back to results

Fat, Inflammation and Insulin Resistance (FIRE)

Primary Purpose

Healthy Adults With Normal BMI

Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Fat/Inflammation effects
Sponsored by
German Diabetes Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Healthy Adults With Normal BMI focused on measuring Healthy adults, Insulin sensitivity

Eligibility Criteria

20 Years - 40 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Healthy male and female subjects
  • Age 20-40
  • BMI 20-25 mg/m2

Exclusion Criteria:

  • Hyperlipidemia
  • Smoking
  • Pregnancy
  • Acute infection
  • Anaemia
  • Taking drugs influencing lipid or glucose metabolism, the immune system or antihypertensive medication
  • Malignancies
  • Any chronic disease
  • Autoimmune or immune compromising diseases including HIV/AIDS
  • Allergies against study drugs
  • Hepatitis
  • Gall bladder diseases
  • Renal failure
  • Psychiatric diseases or addiction

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm 4

    Arm Type

    Active Comparator

    Active Comparator

    Active Comparator

    Placebo Comparator

    Arm Label

    Fat intravenously

    Fat orally

    LPS intravenously

    Glycerol intravenously

    Arm Description

    Intravenous application of fat

    Oral fat load

    Lipopolysaccharide (LPS; US Standard Reference endotoxin)

    Intrevenous glycerol infusion

    Outcomes

    Primary Outcome Measures

    Effect of intervention on whole body insulin sensitivity

    Secondary Outcome Measures

    Effect of intervention on systemic inflammation
    Effect of intervention on cellular immune mechanisms

    Full Information

    First Posted
    January 22, 2010
    Last Updated
    August 18, 2020
    Sponsor
    German Diabetes Center
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT01054989
    Brief Title
    Fat, Inflammation and Insulin Resistance
    Acronym
    FIRE
    Official Title
    Fat, Inflammation and Insulin Resistance (FIRE-Study)
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    August 2020
    Overall Recruitment Status
    Completed
    Study Start Date
    March 15, 2009 (Actual)
    Primary Completion Date
    September 15, 2011 (Actual)
    Study Completion Date
    October 15, 2012 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    German Diabetes Center

    4. Oversight

    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    The combination of impaired insulin sensitivity and insulin secretion is thought to be the basis of type 2 diabetes. Increased free fatty acids levels impair insulin action in muscle and liver, but also systemic inflammation processes play a role in the development of insulin resistance. This study compares the effects of fat and inflammation on insulin sensitivity, systemic inflammation, energy metabolism, vascular system and neural function in healthy humans.
    Detailed Description
    A dysregulation of lipid metabolism with increased levels of free fatty acids (FFA) is known represent one key mechanism in the pathophysiology of insulin resistance, which is subsequently known to be the basis of the development of type 2 diabetes. But also inflammatory processes, also known as subclinical inflammation, have been shown to be independently associated with insulin resistance and diabetes development. The aim of this study is to analyse the causal relationship between FFA and inflammation in the induction of insulin resistance in healthy humans. It is known that the parenteral application of lipids over 4-6 hours results in an increase of FFA and a subsequent induction of a transient insulin resistance in peripheral tissues. Whether oral fat intake has similar effect is still unknown. On the other hand the oral intake of a high fat meal acutely increases intestinal permeability and thereby the levels of bacterial lipopolysaccharide (LPS) in the bloodstream. LPS is known to be a potent stimulator of immune response on a subclinical level accompanied by elevated levels of immune mediators, which in turn impair the insulin receptor signalling pathway leading to insulin resistance. Thus, in this study the effects of fat, both by an oral or parenteral fat load, and by a short-term LPS-infusion simulating the postprandial systemic LPS peak compared to a control infusion (glycerol) on insulin resistance is analysed. Insulin resistance and hepatic glucose production is determined by an hyperinsulinemic euglycemic clamp including glucose tracers. To detect the effects on the immune system on different levels, we measure 1) circulating levels of immune mediators by ELISA and bead-based mulitiplex assays, 2) gene expression of leukocytes, 3) subfractions of circulating leukocytes by FACS and 4) the stimulatory capacity of isolated lymphocytes and monocytes in vitro. Moreover, the effects of fat or inflammation on the function of the autonomic nervous system and the vasculature are studied. A second focus is the impact of the interventions on signal transduction and mitochondrial function in muscle and as well as on the metabolism and inflammation in subcutaneous adipose tissue in muscle and fat biopsies.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Healthy Adults With Normal BMI
    Keywords
    Healthy adults, Insulin sensitivity

    7. Study Design

    Primary Purpose
    Basic Science
    Study Phase
    Phase 4
    Interventional Study Model
    Crossover Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    16 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Fat intravenously
    Arm Type
    Active Comparator
    Arm Description
    Intravenous application of fat
    Arm Title
    Fat orally
    Arm Type
    Active Comparator
    Arm Description
    Oral fat load
    Arm Title
    LPS intravenously
    Arm Type
    Active Comparator
    Arm Description
    Lipopolysaccharide (LPS; US Standard Reference endotoxin)
    Arm Title
    Glycerol intravenously
    Arm Type
    Placebo Comparator
    Arm Description
    Intrevenous glycerol infusion
    Intervention Type
    Biological
    Intervention Name(s)
    Fat/Inflammation effects
    Intervention Description
    Fat infusion (Intralipid) over 6 hours Fat orally (Soy bean oil) single dose LPS infusion for 10 minutes Glycerol infusion over 6 hours
    Primary Outcome Measure Information:
    Title
    Effect of intervention on whole body insulin sensitivity
    Time Frame
    6 hours
    Secondary Outcome Measure Information:
    Title
    Effect of intervention on systemic inflammation
    Time Frame
    1-6 hours
    Title
    Effect of intervention on cellular immune mechanisms
    Time Frame
    6 hours

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    20 Years
    Maximum Age & Unit of Time
    40 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: Healthy male and female subjects Age 20-40 BMI 20-25 mg/m2 Exclusion Criteria: Hyperlipidemia Smoking Pregnancy Acute infection Anaemia Taking drugs influencing lipid or glucose metabolism, the immune system or antihypertensive medication Malignancies Any chronic disease Autoimmune or immune compromising diseases including HIV/AIDS Allergies against study drugs Hepatitis Gall bladder diseases Renal failure Psychiatric diseases or addiction
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Michael Roden, Prof., MD
    Organizational Affiliation
    German Diabetes Center
    Official's Role
    Study Director
    First Name & Middle Initial & Last Name & Degree
    Bettina Nowotny, MD
    Organizational Affiliation
    German Diabetes Center
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    25893426
    Citation
    Ziegler D, Strom A, Strassburger K, Nowotny B, Zahiragic L, Nowotny PJ, Carstensen-Kirberg M, Herder C, Szendroedi J, Roden M. Differential Patterns and Determinants of Cardiac Autonomic Nerve Dysfunction during Endotoxemia and Oral Fat Load in Humans. PLoS One. 2015 Apr 20;10(4):e0124242. doi: 10.1371/journal.pone.0124242. eCollection 2015.
    Results Reference
    derived
    PubMed Identifier
    23454694
    Citation
    Nowotny B, Zahiragic L, Krog D, Nowotny PJ, Herder C, Carstensen M, Yoshimura T, Szendroedi J, Phielix E, Schadewaldt P, Schloot NC, Shulman GI, Roden M. Mechanisms underlying the onset of oral lipid-induced skeletal muscle insulin resistance in humans. Diabetes. 2013 Jul;62(7):2240-8. doi: 10.2337/db12-1179. Epub 2013 Mar 1.
    Results Reference
    derived

    Learn more about this trial

    Fat, Inflammation and Insulin Resistance

    We'll reach out to this number within 24 hrs